What to Expect From Nutrien’s Upcoming Q1 Earnings Results?

RBC Capital analysts provided their outlook on Nutrien (NYSE:NTR), expecting a weak Q1 (scheduled on May 10) and 2023 downward guidance revisions, reflecting a slow start to 2023. RBC Capital estimates quarterly EBITDA of $1.6 billion, compared to the Street estimate of $1.7 billion.

Demand was slower than expected through Q1, despite favorable ag/fertilizer fundamentals, resulting in continued price declines and slow sales. Nitrogen performed worse than anticipated, and there was also a decline in potash.

The analysts lowered their 2023 and 2024 EBITDA estimates to $8.1 billion and $7.9 billion, from $9.0 billion and $8.7 billion, and cut their price target to $100 from $110.

Nutrien (NYSE:NTR) reported its Q4 results last week, with EPS of $2.02 coming in worse than the Street estimate of $2.57, while revenue of $7.53 billion beat the consensus estimate of $7.49 billion.

For fiscal 2023, the company expects EPS in the range of $8.45-$10.65, missing the consensus estimate of $11.49.

RBC Capital analysts think that the agricultural fundamentals are still robust, and that the company's 2023 guide will aid in setting realistic expectations for a potential rebound in fertilizer demand.

The analysts anticipate that the company will continue to generate substantial operating cash flows, though this will be somewhat offset by the increasing capital expenditures required for maintaining and expanding operations. Nonetheless, the company should be able to generate solid free cash flows, which will be used to continue repurchasing shares and paying dividends.

Nutrien (NYSE:NTR) reported its Q4 results last week, with EPS of $2.02 coming in worse than the Street estimate of $2.57, while revenue of $7.53 billion beat the consensus estimate of $7.49 billion.

For fiscal 2023, the company expects EPS in the range of $8.45-$10.65, missing the consensus estimate of $11.49.

RBC Capital analysts think that the agricultural fundamentals are still robust, and that the company's 2023 guide will aid in setting realistic expectations for a potential rebound in fertilizer demand.

The analysts anticipate that the company will continue to generate substantial operating cash flows, though this will be somewhat offset by the increasing capital expenditures required for maintaining and expanding operations. Nonetheless, the company should be able to generate solid free cash flows, which will be used to continue repurchasing shares and paying dividends.

Nutrien (NYSE:NTR) reported its Q4 results last week, with EPS of $2.02 coming in worse than the Street estimate of $2.57, while revenue of $7.53 billion beat the consensus estimate of $7.49 billion.

For fiscal 2023, the company expects EPS in the range of $8.45-$10.65, missing the consensus estimate of $11.49.

RBC Capital analysts think that the agricultural fundamentals are still robust, and that the company's 2023 guide will aid in setting realistic expectations for a potential rebound in fertilizer demand.

The analysts anticipate that the company will continue to generate substantial operating cash flows, though this will be somewhat offset by the increasing capital expenditures required for maintaining and expanding operations. Nonetheless, the company should be able to generate solid free cash flows, which will be used to continue repurchasing shares and paying dividends.